AbbVie Requests FDA Approval for New Route of SKYRIZI® Treatment for Crohn's Disease

AbbVie's New Submission for SKYRIZI® Approval

AbbVie, a global biopharmaceutical leader, recently announced its submission to the U.S. Food and Drug Administration (FDA) for SKYRIZI® (risankizumab-rzaa), seeking approval for a new subcutaneous (SC) induction treatment aimed at adults with moderately to severely active Crohn's disease. This initiative marks a significant step towards enhancing treatment accessibility and convenience for patients battling this chronic inflammatory condition.

Understanding Crohn's Disease

Crohn's disease affects an estimated 1 million Americans and is characterized by unpredictable inflammation of the gastrointestinal tract, often leading to symptoms such as persistent diarrhea and significant abdominal pain. The chronic nature of this disease poses challenges that extend beyond physical health, impacting daily activities and emotional well-being. With its ever-fluctuating symptoms, Crohn's demands innovative treatment options that offer both effectiveness and convenience.

Proposal for Subcutaneous Induction Method

Currently, SKYRIZI is approved for intravenous (IV) induction but this new submission aims to provide patients with an option for SC administration. Dr. Kori Wallace, AbbVie's Vice President and Global Head of Immunology Clinical Development, stated, "Crohn's disease can disrupt daily life and emotional health. Therefore, we invest in research and innovative solutions to elevate the standard of care for affected individuals."

The proposal is buoyed by positive results from the pivotal Phase 3 AFFIRM study, which assessed the safety and efficacy of the SC induction treatment. This large-scale study involved 289 participants and was pivotal in demonstrating that risankizumab can effectively manage the symptoms associated with moderate to severe Crohn's disease.

Efficacy of the AFFIRM Study

The AFFIRM study aimed to measure two primary endpoints: achieving clinical remission as defined by the Crohn’s Disease Activity Index (CDAI) and evaluating endoscopic responses within 12 weeks. Approximately 65% of participants had previously failed advanced therapies, highlighting the need for alternative treatment solutions. The results from this comprehensive study provided compelling evidence of the SC method's potential benefits and indicated that patients could alternate between SC injections and IV infusion depending on their requirements, ensuring flexibility in treatment.

Significance of SKYRIZI® in Treatment Landscape

Since its FDA approval in 2022 as the first interleukin-23 (IL-23) specific inhibitor for Crohn's disease, SKYRIZI has paved the way for new therapeutic approaches. As this latest application awaits review, AbbVie anticipates favorable responses from the FDA, ideally providing individuals with Crohn's disease another effective treatment option.

The Future of Crohn's Disease Management

If approved, this new SC induction method would not only provide convenience for patients who may prefer self-administration but also expands treatment possibilities in a landscape that is continuously evolving. Patients currently receiving IV infusions could maintain their regimen with SC dosing every eight weeks, a significant shift towards enhanced patient autonomy in their treatment plans.

Conclusion

AbbVie’s ongoing commitment to addressing the unmet needs of Crohn's disease patients is evident through its innovative approaches within their research and development strategies. The determination to submit anew for an SC induction method reflects a proactive stance in managing this multifaceted disease, aiming to relieve the burdens it casts upon individuals.

With the advancements in treatments such as SKYRIZI, coupled with the pharmaceutical industry's commitment to addressing chronic illnesses like Crohn's, hope persists for improved quality of life for those affected. As the FDA reviews this latest application, AbbVie remains dedicated to continuing its contributions to the field of immunology and patient care at large.